Start-up Nuron snags 1st licensing deal, with Mitsubishi, and advances PhIII MS drug
This article was originally published in Scrip
Executive Summary
Nuron Biotech, a two-year old privately held US biologics and vaccines company, has brought in its first licensing deal. It has signed an agreement with Mitsubishi Tanabe Pharma of Osaka, Japan, to commercialise its HibTiter vaccine (Haemophilus b conjugate vaccine [diphtheria CRM197 protein conjugate]) in Japan, both as a single entity and for combination product use.